Healios KKHLOSF 57 PS Ratio is 450.00 as of Jul. 03, 2026, which is 48% below its 10-year median of 871.88. GuruFocus rates HLOSF with a GF Score™ of 57/100 and a GF Value™ of $0.33 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 933 Biotechnology companies, Healios KK ranks worse than 92.39% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Healios KK's share price is $1.80.
Healios KK's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Hence, Healios KK's PS Ratio for today is 450.00.
The historical rank and industry rank for Healios KK's PS Ratio or its related term are showing as below:
HLOSF'
s PS Ratio Range Over the Past 10 Years
Min: 27.76 Med: 871.88 Max: 13803.92
Current: 352.94
During the past 12 years, Healios KK's highest PS Ratio was 13803.92. The lowest was 27.76. And the median was 871.88.
HLOSF's PS Ratio is ranked worse than 92.39% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs HLOSF: 352.94
Healios KK revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Healios KK was -89.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -10.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 32.70% per year.
During the past 12 years, Healios KK's highest 3-Year average Revenue per Share Growth Rate was 107.00% per year. The lowest was -55.90% per year. And the median was -4.60% per year.
Back to Basics: PS Ratio
Healios KK (OTCPK:HLOSF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Healios KK PS Ratio Related Terms
Healios KK PS Ratio Historical Data
* Premium members only.
The historical data trend for Healios KK's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Healios KK's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healios KK PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Healios KK's PS Ratio distribution charts can be found below:
* The bar in red indicates where Healios KK's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Healios KK's Share Price of today is $1.80. Healios KK's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Healios KK (HLOSF) has a PS Ratio of 450.00 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Healios KK and its competitors. This is 48% below median its historical median of 871.88. Over the past decade, Healios KK's PS Ratio has ranged from 27.76 to 13,803.92. According to the industry distribution chart, Healios KK ranks #862 out of 933 companies in the Biotechnology industry, placing it in the top 92.4%.
Is Healios KK's PS Ratio too high?
Healios KK's current PS Ratio of 450.00 is 48% below median its 10-year median of 871.88. Over the past 10 years, this metric has ranged from a low of 27.76 to a high of 13,803.92. The Biotechnology industry median PS Ratio is 9.64. Healios KK's value of 450.00 is 4568% above this industry median. Based on the distribution chart, Healios KK ranks #862 out of 933 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Healios KK has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Healios KK ranks #862 out of 933 companies for PS Ratio. This places Healios KK in the lower half of its industry. The industry median PS Ratio is 9.64. Healios KK's value of 450.00 is 4568% above this benchmark. Historically, Healios KK's own PS Ratio has ranged from 27.76 to 13,803.92 over the past decade. While the company's 10-year median is 871.88 vs. the industry median of 9.64, Healios KK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healios KK's current PS Ratio of 450.00 is 4568% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Healios KK and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healios KK's current PS Ratio is 450.00, which is 48% below median its own 10-year median of 871.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (HLOSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.33, compared to a current price of $1.80 — trading 445.5% above its estimated fair value. The current PS Ratio is 450.00, which is 48% below median its 10-year median of 871.88 and 4568% above the Biotechnology industry median of 9.64. Healios KK's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Healios KK (HLOSF), the current PS Ratio is 450.00 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healios KK (HLOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Healios KK stock appears to be overvalued.
The current stock price of $1.80 is trading 445.5% above its estimated GF Value™ of $0.33.
GuruFocus considers Healios KK to be Significantly Overvalued.
Key valuation signals for HLOSF:
PS Ratio: 450.00 (48% below median its 10-year median of 871.88)
GF Value™: $0.33 vs. price of $1.80 (445.5% above fair value)
Industry Position: 4568% above the Biotechnology median (#862 of 933)
No single metric tells the full story. See the HLOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
57GF Score
Get the complete analysis for HLOSF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLOSF has been successfully added to your 
